My Cart [ 0 ]
Home > Antibodies > A-Z Primary Antibodies > Ranibizumab Biosimilar, VEGF Monoclonal Antibody Fab

Ranibizumab Biosimilar, VEGF Monoclonal Antibody Fab

Anti-VEGF-A Humanized Monoclonal Antibody (Fab)

Catalog No. Product Name Size List Price (US$) Quantity
C005P Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab) 5 mg 3000.00
C005P Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab) 10 mg 5000.00
Description

C005P: Ranibizumab Biosimilar, Human VEGF Monoclonal Antibody Fragment (Fab)

Recombinant Humanized Monoclonal Antibody Fragment (Fab) generated from the same parent mouse antibody as bevacizumab.
Source: The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.
Specificity/Sensitivity: The Fab protein ranibizumab specifically binds to the human VEGF-A.
Applications: Functional assay, neutralization.
Form of Antibody: 0.2 uM filtered solution, pH 5.3, no stabilizers or preservatives.
Endotoxin: < 0.1 EU per 1 ug of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The Fab protein ranibizumab is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.

Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Syd Labs also provides the following VEGF-A antibody biosimilar protein:
Bevacizumab Biosimilar (complete antibody produced in CHO)

Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)

Related Links

See our Privacy Policy